What happens next following FDA approval of Mounjaro® from Eli Lilly for diabetes?

The FDA on May 13th approved the dual GIP-GLP1-agonist Mounjaro┬« (tirzepatide) from Eli Lilly for diabetes following the completion of the SURPASS studies (e.g. SURPASS-2 NCT03987919). Mounjaro┬« is administered as a weekly injection just like the GLP1-agonist Ozempic┬« (semaglutide) from Novo Nordisk for diabetes. The table below summarizes products from Eli Lilly and Novo Nordisk …

Novo Nordisk 2021Q3 – Wegovy┬« bottlenecks

Novo Nordisk continues to succeed in the GLP-1 space with semaglutide (Ozempic┬«, Rybelsus┬« and Wegovy┬«). Highlights of the quarter include initiation of phase 3a trials with oral semaglutide in obesity and ziltivekimab in cardiovascular disease. Novo Nordisk now has late stage clinical trials in all of their therapy areas. Ozempic┬« continues to be one of …

Novo Nordisk Q2 saw approval of Wegovy® and continued growth of Ozempic® sales

Novo Nordisk sales and operating profit grew at 12% and 9%, respectively, at constant exchange rates. The FDA approved the once-weekly injectable anti-obesity drug Wegovy┬« (semaglutide) on June 4th. The figures below summarize the global sales for Novo Nordisk by geography, by drug and by drug class. All geographic markets have experienced growth, but Victoza┬« …

Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19

Novo Nordisk has gained market share in diabetes (29.2%), GLP-1 (49.9%) and insulin (44.5%). The gain in market share has happened with a change in market value in the US as a backdrop; i.e. GLP-1 up and insulin down. As a consequence approximately 70% of sales in the US did not exist 5 years ago. …

Visualization of growth in the COVID-19 impacted quarters

The first and second quarter of 2020 were unusual in many ways. More than a third of S&P500 companies temporarily or permanently withdrew guidance for the full year due to uncertainty surrounding impacts from COVID-19 according to FactSet. This article seeks to visualize the growth in each of the two quarters by sector and industry. …

Best selling and fastest growing drugs in the 2nd quarter of 2020

Best selling drugs Once more Humira┬« from AbbVie is the best selling drug of the quarter ($4,837M) despite headwinds in Europe from biosimilars Amgevita┬«, Amsparity┬«, Halimatoz┬«, Hefiya┬«, Hulio┬«, Hyrimoz┬«, Idacio┬« and Imraldi┬«. In the US Humira┬« will in 2023 lose market exclusivity to the biosimilars Amjevita┬«, Cyltezo┬«, Hyrimoz┬«, Hadlima┬«, Abrilada┬« and Hulio┬«. AbbVie upon acquisition …

Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus®

Novo Nordisk has reported their 2nd quarter results. Financials For the 2nd quarter sales were DKKm 30,006 (-0%), gross profit was DKKm 25,234 and operating income was DKKm 13,838 (+3%). In the US GLP1 for diabetes increased by 19%, whereas insulin decreased by 34%. CEO Lars Fruergaard J├Şrgensen “The U.S. sales decline was driven by …

Sector sizes of the S&P 500 over time

Dot-com bubble The largest sectors and companies of the S&P 500 by market capitalization have changed over time. Prior to the dot-com bubble bursting in March 2000 the technology sector made up a third of the S&P 500 thanks to companies such as Microsoft, Cisco, Intel, Lucent Technologies, IBM, America Online and Oracle. 2007-2008 financial …

Novo Nordisk mostly unaffected by COVID-19 in Q1

Novo Nordisk is with the exception of the postponement of new clinical trials mostly unaffected by COVID-19. Sales in Q1 were however positively affected by stock piling of insulin. Growth continues to be spearheaded by Ozempic┬«, whereas Victoza┬« and Levemir┬« in the US continue to lead the decline. Rybelsus┬« revenue totaled DKKb 229 in the …

Kraft Heinz can pay down its $29B debt and maintain its $2B dividend

Organic net sales down 2% due to volume/mix declines in response to higher pricing in the US and to a lesser extent lower pricing in Canada Further impairments of goodwill (453 USDm) and intangible assets (224 USDm) Strategy presentation will be in early May and not in March. No guidance or outlook for 2020 has …